UFF
CRMD icon

USA Financial Formulas’s CorMedix CRMD Stock Holding History

USA Financial Formulas’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,461
Closed -$55K – 270
2025
Q2 		$55K Buy
+4,461
New +$49.2K 0.01% 203

Other funds holding CRMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

USA Financial Formulas's CRMD Position: Q3 2025 in Review

USA Financial Formulas sold out of CorMedix (CRMD) in Q3 2025, closing a stake of 4,461 shares — an estimated $55K sold.

USA Financial Formulas first reported a position in CRMD in Q2 2025 and held it in 1 quarter. The position peaked at $55K in Q2 2025. 190 funds tracked by Wall St. Rank hold CRMD as of Q3 2025.

  • USA Financial Formulas reported no remaining CorMedix position as of Q3 2025 after selling out during the quarter.
  • USA Financial Formulas sold 4,461 CorMedix shares in Q3 2025, an estimated $55K.
  • USA Financial Formulas first reported a position in CorMedix in Q2 2025 and held it in 1 quarter.
  • USA Financial Formulas's CorMedix position peaked at $55K in Q2 2025.
  • 190 funds tracked by Wall St. Rank held CorMedix as of Q3 2025.

Based on USA Financial Formulas's 13F filing for Q3 2025, filed 10 Oct 2025.